
| Disease Domain | Count |
|---|---|
| Infectious Diseases | 2 |
| Immune System Diseases | 1 |
| Top 5 Drug Type | Count |
|---|---|
| Enzyme | 1 |
| Bacteriophage therapy | 1 |
| Top 5 Target | Count |
|---|---|
| Peptidoglycan | 1 |
Target- |
Mechanism- |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePhase 1 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism Peptidoglycan modulators |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhasePhase 1 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date20 Nov 2024 |
Sponsor / Collaborator |
Start Date01 Jan 2022 |
Sponsor / Collaborator |
Start Date01 Jan 2022 |
Sponsor / Collaborator |

| Drug(Targets) | Indications | Global Highest Phase |
|---|---|---|
PGX-0100 | Wound Infection More | Phase 1 |
Staphylococcus lysin ( Peptidoglycan ) | Prosthetic joint infection More | Phase 1 |
Bacteriophage therapy(Phagelux) | Pressure Ulcer More | Pending |





